Probiotics reduced IBS symptom scores in a placebo-controlled trial
In people with irritable bowel syndrome, probiotics produced lower symptom-severity scores than placebo from week 8. The abstract does not report the size of that score difference.
Based on the published abstract. The full paper may contain additional methods, results and limitations.
The 30-second takeaway
In this randomized trial, people receiving probiotics had lower irritable bowel syndrome symptom scores than those receiving placebo from week 8. Laboratory measures also changed, and symptom improvement correlated with increases in short-chain fatty acids. These accompanying changes do not establish the pathway causing symptom relief, and the abstract leaves the improvement's magnitude unclear.
The abstract does not give probiotic strains, dose, symptom-score differences or confidence intervals. Although follow-up was planned, it does not separately describe whether symptom improvements persisted after supplementation ended.
What researchers found
IBS Symptom Severity Scale
Probiotics versus placebo during a 12-week intervention; significant group differences were reported from week 8, but no score difference or confidence interval was supplied.
Symptoms were the main outcome
The trial's main outcome was a symptom-severity score. Researchers separately measured stool short-chain fatty acids, intestinal permeability, meaning passage through the intestinal barrier, and inflammatory markers; these laboratory outcomes were distinct from symptom relief.
Reported tolerability remains uncertain
Adherence and adverse-event occurrence did not differ significantly between groups. That result does not establish equal safety, particularly because the abstract provides neither event counts nor descriptions of the adverse events.
The original publication
Effects of short-chain fatty acid-producing probiotic metabolites on symptom relief and intestinal barrier function in patients with irritable bowel syndrome: a double-blind, randomized controlled trial.
Li E, Wang J, Guo B et al.
Front Cell Infect Microbiol · 2025
- PubMed ID
- 40575487
- Record checked
AI-assisted research and writing. This explains one selected publication; it is not a complete review of everything known. Our approach.
One more question, understood.
Keep track of the research you’ve explored.